Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020
23 April 2020 - 9:30PM
Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today
announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two
studies investigating intratumoral tilsotolimod, Idera’s
investigational Toll-like receptor 9 (TLR9) agonist, will be
presented at the American Association for Cancer Research (AACR)
Virtual Annual Meeting I, to be held April 27-28, 2020, as part of
a “Clinical Trial Poster Session.”
ILLUMINATE-206 is an ongoing phase 2, open-label, multicohort,
multicenter study to test the safety and efficacy of intratumoral
tilsotolimod in combination with Yervoy®* (ipilimumab) and Opdivo®
(nivolumab) for the treatment of solid tumors. The trial initiated
in September 2019 with the microsatellite stable colorectal cancer
(MSS-CRC) cohort. A description of the trial in progress will be
presented.
ILLUMINATE-101 was a phase 1b trial of intratumoral tilsotolimod
monotherapy in patients with refractory solid tumors, which was
completed in December 2019. Final results will be presented.
Hani M. Babiker, M.D., from the University of Arizona Cancer
Center will present both studies. The abstract titles are as
follows:
- Abstract # 10614: Tilsotolimod engages the TLR9 pathway to
promote antigen presentation and Type-I IFN signaling in solid
tumors
- Abstract # 10591: A phase 2 multicenter study to evaluate the
efficacy of tilsotolimod in combination with nivolumab and
ipilimumab for treatment of microsatellite-stable colorectal cancer
(ILLUMINATE-206)
“We are very pleased that Dr. Babiker from the University of
Arizona Cancer Center will present information from our studies
investigating tilsotolimod in solid tumors,” stated Elizabeth
Tarka, M.D., Idera’s Chief Medical Officer. “We continue to be
excited about the broader potential of tilsotolimod beyond
melanoma.”
The abstracts and video presentations will be available at 12:01
AM ET on Monday, April 27. Video presentations will be available
for viewing on demand through the virtual meeting platform.
About Tilsotolimod (IMO-2125)
Tilsotolimod is an investigational, synthetic Toll-like receptor
9 agonist. Intratumoral injection of tilsotolimod has been shown to
promote both innate and adaptive immune activation. Tumors with an
active immune response appear to respond better to CPIs than those
that exclude or inhibit anti-tumor immune cells. Tilsotolimod in
combination with CPIs may cause regression of locally injected and
distant tumor lesions and increase the number of patients who
benefit from immunotherapy.
Tilsotolimod has received both Fast Track designation and Orphan
Drug designation from the FDA and is being evaluated in multiple
tumor types and in combination with multiple checkpoint and
costimulation therapies. For more information on tilsotolimod
trials, please visit ClinicalTrials.gov.
About Idera Pharmaceuticals
Harnessing the approach of the earliest researchers in
immunotherapy and the company’s vast experience in developing
proprietary immunology platforms, Idera’s development program is
focused on priming the immune system to play a more powerful role
in fighting cancer, ultimately increasing the number of people who
can benefit from immunotherapy. Idera also continues to focus on
the acquisition, development, and ultimate commercialization of
drug candidates for both oncology and rare disease indications
characterized by small, well-defined patient populations with
serious unmet needs. To learn more about Idera, visit
IderaPharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements, other than statements of historical fact,
included or incorporated in this press release, including
statements regarding the Company's strategy, future operations,
collaborations, intellectual property, cash resources, financial
position, future revenues, projected costs, prospects, clinical
trials, plans, and objectives of management, are forward-looking
statements. The words "believes," "expects," "anticipates,"
"estimates," "plans," "expects," "intends," "may," "could,"
"should," "potential," "likely," "projects," "continue," "will,"
and "would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Idera cannot guarantee
that it will actually achieve the plans, intentions or expectations
disclosed in its forward-looking statements and you should not
place undue reliance on the Company's forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated or implied
by its forward-looking statements. Factors that may cause such a
difference include: whether the Company’s cash resources will be
sufficient to fund the Company’s continuing operations and the
further development of the Company’s programs for the period
anticipated; whether interim results from a clinical trial, such as
the preliminary results reported in this release, will be
predictive of the final results of the trial; whether results
obtained in preclinical studies and clinical trials such as the
results described in this release will be indicative of the results
that will be generated in future clinical trials, including in
clinical trials in different disease indications; whether products
based on Idera's technology will advance into or through the
clinical trial process when anticipated or at all or warrant
submission for regulatory approval; whether such products will
receive approval from the U.S. Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the Company's collaborations will be
successful; and such other important factors as are set forth under
the caption "Risk factors" in the Company’s Annual Report filed on
Form 10-K for the period ended December 31, 2019. Although Idera
may elect to do so at some point in the future, the Company does
not assume any obligation to update any forward-looking statements
and it disclaims any intention or obligation to update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
*Yervoy (ipilimumab) and Opdivo (nivolumab) are registered
trademarks of Bristol Myers Squibb.
IDERA PHARMACEUTICALS Contacts:
Jill Conwell Investor Relations & Corporate Communications
Phone (484) 348-1675JCONWELL@IDERAPHARMA.COM
John J. KirbyChief Financial OfficerPhone (484)
348-1627JKIRBY@IDERAPHARMA.COM
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2024 to May 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From May 2023 to May 2024